Soligenix, Inc. · NASDAQ:SNGX

Soligenix — Investor Presentation (January 2017)

25 slides from Soligenix's investor presentation, January 2017

  1. Slide 1: Rising to the Challenges of Rare Disease Treatment

    … Rising to the Challenges of Rare Disease Treatment NASDAQ: SNGX

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products a

  3. Slide 3: Company Highlights

    Company Highlights  Diversified product portfolio in advanced development, targeting rare disease indications in inflammation, oncology and biodefense with $200M+ markets worldwide o Phase 3 clinical program for the treatment of cutaneous T-cell lymphoma (SGX301) - Orphan drug and fast track design

  4. Slide 4: Rare Disease Pipeline

    Rare Disease Pipeline BioTherapeutics Product Candidates Preclinical Phase 1 Phase 2 Phase 3 Market SGX301 ORPHAN & FAST TRACK DESIGNATIONS Enrolling; Ph. 3 data 2H 2017* Cutaneous T-Cell Lymphoma (CTCL) SGX942 FAST TRACK DESIGNATION Ph. 3 data 2H 2018* Oral Mucositis in Head & Neck Cancer** SGX203

  5. Slide 5: Multiple Potential Value Drivers

    Multiple Potential Value Drivers 2016 2017 2018 SGX301 EU orphan drug 1H: Ph. 3 complete 2H: Ph. 3 data 1H: NDA designation CTCL enrollment CTCL submission CTCL SGX942* Positive Ph. 2 data 1H: Ph. 3 start 1H: Ph. 3 Interim 2H: Ph. 3 data in Oral Mucositis Oral Mucositis Analysis Oral Mucositis FDA c

  6. Slide 6: Significant WW Market Potential

    Significant WW Market Potential $500+ Assumptions(1) 500 $450 Oral Mucositis in Head and Neck Cancer 450 90,000 Patients US 90,000 Patients EU 400 Cutaneous T-Cell Lymphoma 20,000 Patients US 350 $ Millions $300 20,000 Patients EU 300 Pediatric Crohn’s Disease 80,000 Patients US $250 250 80,000 Pati

  7. Slide 7: Experienced Management and Board of Directors

    Experienced Management and Board of Directors • 27 years of experience • Discovery Laboratories (COO) Christopher J. • Acute Therapeutics (Co-Founder) Keith • 35 years of experience Schaber, PhD Brownlie, CPA • Ernst & Young President & CEO • Ohmeda Pharmaceuticals • The Liposome Company • Wyeth Aye

  8. Slide 8: BioTherapeutics

    BioTherapeutics Targeted Approach to Treating Oncology & Inflammation 8

  9. Slide 9: BioTherapeutics Business Segment

    BioTherapeutics Business Segment Commercial targets – unmet medical needs in oncology and inflammation BioTherapeutics Product Candidates Preclinical Phase 1 Phase 2 Phase 3 Market SGX301 ORPHAN & FAST TRACK DESIGNATIONS Enrolling; Ph. 3 data 2H 2017* Cutaneous T-Cell Lymphoma (CTCL) SGX942 FAST TRA

  10. Slide 10: Cutaneous T-Cell Lymphoma – Disease Overview

    Cutaneous T-Cell Lymphoma – Disease Overview Atypical T-cells in dermis  Cutaneous T-cell lymphoma (CTCL) o Rare class of Non-Hodgkin's Lymphoma (NHL) o Malignant T-cells migrate to the skin o Cancer forms patches or lesions  CTCL affects over 40,000 NHL patients worldwide; currently no cure  Two

  11. Slide 11: SGX301 – Synthetic Hypericin

    SGX301 – Synthetic Hypericin SGX301 is a first-in-class, topical drug applied to CTCL skin lesions followed by activation with safe, visible, fluorescent light to kill malignant T-cells  Affects over 40,000 patients annually worldwide  No approved front-line therapy for early stage (I-IIA) CTCL (~

  12. Slide 12: SGX301 – Phase 2 Response Rate

    SGX301 – Phase 2 Response Rate CTCL Patch Hypericin Therapy CTCL Patch Pre-Therapy Using Visible Light Post -Therapy Summary of CTCL Lesion Responses to Synthetic Hypericin Ointment Following Six Weeks of Treatment Responders/Total Percent Responders Hypericin Responders 7/12 58.3% Placebo Responder

  13. Slide 13: Oral Mucositis – Disease Overview

    Oral Mucositis – Disease Overview Inflammation causes worsening damage Ref: S. Sonis 2004  Oral mucositis (OM) Secondary infection o Multi-factorial disease linked to a dysregulation of the innate immune system  OM affects over 180,000 head and neck (H&N) cancer patients worldwide  Debilitating s

  14. Slide 14: SGX942 – Innate Defense Regulator

    SGX942 – Innate Defense Regulator SGX942 (dusquetide) is a first-in-class, injectable drug, called an Innate Defense Regulator (IDR), that modulates the body’s innate immune system to reduce inflammation  OM affects over 180,000 H&N cancer patients worldwide  No approved drug for OM in H&N cancer;

  15. Slide 15: SGX942 – Oral Mucositis Results

    SGX942 – Oral Mucositis Results  Clinically Meaningful Results demonstrated in the 1.5 mg/kg dose group versus placebo at one month following completion of chemoradiation therapy o Primary Endpoint – Decrease in the duration of severe OM o Primary endpoint outcome consistent with multiple key secon

  16. Slide 16: SGX942 – Oral Mucositis Results

    SGX942 – Oral Mucositis Results  Clinically Meaningful Results demonstrated in SGX942 1.5 mg/kg dose group versus placebo one month following completion of chemoradiation in patients at higher risk for severe OM receiving aggressive chemotherapy (80-100 mg/m2) o Relative 22% decrease in duration of

  17. Slide 17: Pediatric Crohn's Disease – Disease Overview

    Pediatric Crohn’s Disease – Disease Overview Normal mucosa under endoscopy  Pediatric Crohn’s disease o Chronic inflammatory disorder of the gastrointestinal (GI) tract o Diarrhea, rectal bleeding and abdominal pain  Resulting in growth failure, malnutrition, pubertal delay and bone demineralizati

  18. Slide 18: SGX203 – Beclomethasone Dipropionate

    SGX203 – Beclomethasone Dipropionate SGX203 is a proprietary oral formulation of immediate and delayed release beclomethasone 17,21-dipropionate (BDP) tablets to treat GI inflammation with less toxicity than the current standard systemic steroid therapy  160,000 children/adolescents with Crohn’s di

  19. Slide 19: Vaccine/BioDefense

    Vaccine/BioDefense Addressing Critical Concerns for Industry and Government 19

  20. Slide 20: Vaccine/BioDefense Business Segment

    Vaccine/BioDefense Business Segment Funded by Government – Medical Countermeasures for Civilian and Military Use Vaccines / BioDefense** Product Candidates (FDA Animal Rule) Proof-of-Concept Animal Phase 1 Phase 2/3 Market ThermoVax® (TVax) VACCINE PLATFORM Ebola Vaccine Collaboration; Heat Stabiliz

  21. Slide 21: ThermoVax – Vaccine Thermostability Platform

    ThermoVax® – Vaccine Thermostability Platform % Im m u n o g e n ic ity ThermoVax® is a proprietary 100 freeze-drying process that o 4 0 C T h e rm o V a x Positive results: enables vaccines to be stored 50 o 4 0 C O r ig in a l o Ricin vaccine without refrigeration o Anthrax vaccine o HPV vaccine D

  22. Slide 22: RiVax – Ricin Toxin Vaccine

    RiVaxTM – Ricin Toxin Vaccine 100 Heat-stable ricin vaccine provided * L a te d e a th n o t d ire c tly 100% protection in a non-human % S u r v iv a l 75 a ttrib u te d to ric in in to x ic a tio n primate aerosol challenge model V a c c in e (N = 1 2 ) (right) 50 S h a m (N = 6 ) Demonstrated saf

  23. Slide 23: OrbeShield for GI Acute Radiation Syndrome

    OrbeShield® for GI Acute Radiation Syndrome Two-tablet BDP system also 100 efficacious in animal models of % S u r v iv a l 75 gastrointestinal acute radiation syndrome (GI ARS) 50 B D P (N = 6 ) Preliminary proof of concept data 25 P la c e b o (N = 4 ) in canine model of GI ARS (right) p < 0 .0 5

  24. Slide 24: Investment Highlights

    Investment Highlights  Diversified product portfolio in advanced development, targeting rare disease indications in inflammation, oncology and biodefense with $200M+ markets worldwide o Phase 3 clinical program for the treatment of cutaneous T-cell lymphoma (SGX301) - Orphan drug and fast track des

  25. Slide 25: Thank You

    Rising to the Challenges of Rare Disease Treatment THANK YOU www.soligenix.com

Soligenix — Investor Presentation (January 2017) on 6ix